Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
2008-01-22
2008-01-22
Weber, Jon (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
C435S024000, C435S007720
Reexamination Certificate
active
07320878
ABSTRACT:
The present invention concerns a further development and use of biological assays to determine the amount or concentration of an active ingredient present in a sample. The enzyme assay of the present invention determines the amount or concentration of protease inhibitors, including retroviral protease inhibitors such as HIV inhibitors.
REFERENCES:
patent: 4546076 (1985-10-01), Degelaen et al.
patent: 4918001 (1990-04-01), Kolde
patent: 5576177 (1996-11-01), Fridland et al.
patent: 5843946 (1998-12-01), Vazquez et al.
patent: 6017723 (2000-01-01), Rao et al.
patent: 6243980 (2001-06-01), Bronstein et al.
patent: 0 428 000 (1991-05-01), None
patent: 0 518 557 (1992-12-01), None
patent: WO 97/27319 (1997-07-01), None
patent: WO 97/27480 (1997-07-01), None
patent: WO 99/50579 (1999-10-01), None
patent: WO 99/54734 (1999-10-01), None
patent: WO 99/67417 (1999-12-01), None
patent: WO 01/57245 (2001-08-01), None
patent: WO 02/23186 (2001-09-01), None
patent: WO 01/79540 (2001-10-01), None
patent: WO 02/23186 (2002-03-01), None
patent: WO 02/38792 (2002-05-01), None
Guidance for Industry; U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Nov. 1999.□□Http://www.fda.gov/cder/guidance/2635fnl.pdf.
Zhang et al. Drur Resistance During Indinavir Therapy is Caused by Mutations in the Protease Gene and in its Gag Substrate Cleavage Sites: Journal of Virology, vol. 71, No. 9 (1997) pp. 6662-6670.
Vance et al. Conformational Selectivity of HIV-1 Protease Cleavage of X-Pro Peptide Bonds and its Implications; The Journal of Biological Chemistry, vol. 272, No. 25 (1997) pp. 15603-15606.
Aarnoutse, Re, et al., “High-Performance Liquid Chromatography of HIV-Protease Inhibitors in Human Biological Matrices”Journal of Chromatography, 2001, 764, 363-384.
Dailly, E. et al., “High-Performance Liquid Chromatographic Assay to Determine the Plasma Levels of HIV-Protease Inhibitors (Amprenavir, Indinavir, Nelfinavir, Ritonavir and Saquinavir) and the Non-Nucleoside Reverse Transcriptase Inhibitor (Nevirapine) after Liquid-Liquid Extraction”,Journal of Chromatography B2001, 758(2), 129-135.
Gulnik, S. et al., “Enzymatic Bioassay for Therapeutic Drug Monitoring of HIV Protease Inhibitors”,Antiviral Therapy, 2002, 7, S78.
Kakiuchi, N., et al. “A High Throughput Assay of the Hepatitis C Virus Nonstructural Protein 3 Serine Proteinase”,Journal of Virological Methods, 1999, 80, 77-84.
Leela, John et al., “Role of Therapeutic Drug Monitoring for Protease Inhibitors”,The Annals of Pharmacotherapy, 2001, 35(6), 745-754.
Marzolini, C. et al., “Simultaneous Determination of the HIV Protease Inhibitors Indinavir, Amprenavir, Saquinavir, Ritonavir, Nelfinavir and the Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz by High-Performance Liquid Chromatography after Solid-Phase Extraction”,Journal of Chromatography B., 2000, 740(1), 43-58.
Matayoshi, E.D. et al., “Novel Flurogenic Substrates for Assaying Retroviral Proteases by Resonance Energy Transfer”,Science, 1990, 247, 954-958.
Moyle, GJ. et al., “Principles and Practice of HIV-Protease Inhibitor Pharmacoenhancement”,HIV Medicine, 2001, 2, 105-113.
Taliani, M. et al., “A Continuous Assay of Hepatitis C Virus Protease Based on Resonance Energy Transfer Depsipeptide Substrates”,Analytical Biochemistry, 1996, 240, 60-67.
Zhang, R. et al., “A Continuous Spectrophotometric Assay for the Hepatitis C Virus Serine Protease”,Analytical Biochemistry, 1999, 270, 268-275.
Toth, M.V. et al., “A Simple, Continuous Flurometric Assay for HIV Protease”,Int. J. Peptide Protein Res., 1990, 36(6), 544-550.
Tyagi, S.C. et al., “Continuous Assay of the Hyrdolytic Activity of Human Immunodeficiency Virus-1 Protease”,Analytical Biochemistry, 1992, 200(1), 143-148.
Villani, P. et al., “Antireovirals: Simultaneous Determination of Five Protease Inhibitors and Three Nonnucleoside Transcriptase Inhibitors in Human Plasma by a Rapid High-performance Liquid Chromatography-Mass Spectrometry Assay”,Therapeutic Drug Monitoring., 2001, 23(4),380-388.
Wang, G.T. et al., “Design and Synthesis of New Flurogenic HIV Protease Substrates Based on Resonance Energy Transfer”,Tetrahedron Letters, 1990, 31(45), 6493-6496.
Warner, A., “Setting Standards of Practice in Therapeutic Drug Monitoring and Clinical Toxicology: A North American View”,Therapeutic Drug Monitoring, 2001, 23(2),93-97.
Erickson John W
Gulnik Sergei
Markowitz Martin
Yu Betty
Aaron Diamond Aids Research Center
Martin Paul
The Rockefeller University
Tibotec Pharmaceuticals Ltd.
Weber Jon
LandOfFree
Protease assay for therapeutic drug monitoring does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protease assay for therapeutic drug monitoring, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease assay for therapeutic drug monitoring will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2789706